Sarepta Therapeutics (NASDAQ:SRPT) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.
Profitability
This table compares Sarepta Therapeutics and Kronos Bio's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Sarepta Therapeutics | -121.30% | -61.62% | -23.02% |
Kronos Bio | N/A | N/A | N/A |
Valuation & Earnings
This table compares Sarepta Therapeutics and Kronos Bio's gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Sarepta Therapeutics | $380.83 million | 14.47 | $-715,080,000.00 | ($9.71) | -7.15 |
Kronos Bio | N/A | N/A | N/A | N/A | N/A |
Kronos Bio has lower revenue, but higher earnings than Sarepta Therapeutics.
Insider and Institutional Ownership
89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Sarepta Therapeutics and Kronos Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Sarepta Therapeutics | 1 | 9 | 12 | 0 | 2.50 |
Kronos Bio | 0 | 0 | 4 | 0 | 3.00 |
Sarepta Therapeutics presently has a consensus target price of $150.4762, suggesting a potential upside of 116.89%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Kronos Bio.
Summary
Sarepta Therapeutics beats Kronos Bio on 5 of the 9 factors compared between the two stocks.